Lv3
380 积分 2021-12-30 加入
Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT)
6天前
已完结
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001)
15天前
已完结
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
21天前
已完结
Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-T alone in relapsed/refractory large B-cell lymphoma
22天前
已完结
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
26天前
已完结
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
28天前
已完结
Emerging first-line treatment approaches for mantle cell lymphoma
1个月前
已完结
Assessing adverse event burden in chronic lymphocytic leukemia treatment regimens: what’s best for patient quality of life?
1个月前
已完结
Considerations for the treatment of older adults with chronic lymphocytic leukemia
1个月前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2个月前
已完结
皖公网安备34019202002308
